Q4 2017 Meddevicetracker Outlook Report
Q4 2017 Meddevicetracker Outlook Report
$4,750.00
In this report, we cover catalysts from 9 devices expected to occur in Q4 2017, along with an overview of selected presentations from the upcoming Transcatheter Cardiovascular Therapeutics (TCT) Conference. The last page of this report contains an excel sheet of the Large Impact Catalysts expected to occur in Q4 2017.
- Description
- Contents
- Samples
In this report, we cover catalysts from 9 devices expected to occur in Q4 2017, along with an overview of selected presentations from the upcoming Transcatheter Cardiovascular Therapeutics (TCT) Conference. The last page of this report contains an excel sheet of the Large Impact Catalysts expected to occur in Q4 2017.
Disease Groups Covered:
- Cardiovascular
- Endocrine
- Neurology
- Oncology
CONTENTS
CENTERA Transcatheter Heart Valve for Cardiac Valve Surgery (EW) …………………………………………………… 4
Diabeloop System for Diabetes Mellitus, Type I ……………………………………………………………………………….. 5
Eversense for Diabetes Mellitus, Type I & II (SENS) …………………………………………………………………………… 6
Focal One for Prostate Cancer (EDAP) ……………………………………………………………………………………………. 7
Guardian REAL-Time CGM System for Diabetes Mellitus, Type I & II (MDT) ………………………………………….. 8
Lotus Valve for Cardiac Valve Surgery (BSX)…………………………………………………………………………………… 10
Nellix Endovascular Aneurysm Sealing System for Aortic Aneurysm (ELGX) ………………………………………… 11
neuroAD for Alzheimer’s Disease ………………………………………………………………………………………………… 12
Vagus Nerve Stimulation (VNS) Therapy System for Seizure Disorders (LIVN) ……………………………………… 13
2017 Transcatheter Cardiovascular Therapeutics (TCT) Select Presentations ………………………………………. 14
Fantom Bioresorbable Scaffold for Coronary Artery Disease (RVALL) ………………………………………….. 14
COMBO for Coronary Artery Disease …………………………………………………………………………………….. 15
Absorb BVS for Coronary Artery Disease (ABT) ……………………………………………………………………….. 15
Harpoon Mitral Valve System for Cardiac Valve Surgery …………………………………………………………… 16
WATCHMAN for Stroke Prevention in Atrial Fibrillation (SPAF) (BSX) ………………………………………….. 17
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Biomedtracker Q4 2017 Outlook Report